Previous 10 | Next 10 |
ENGLEWOOD, CO / ACCESSWIRE / November 23, 2021 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company focused on commercializing novel therapeutics and consumer healthcare products, announced that today the United States Patent and Trademark Office (USPTO) has issued a U.S....
ENGLEWOOD, CO / ACCESSWIRE / November 17, 2021 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company focused on commercializing novel therapeutics and consumer healthcare products, today announced it ranked 178 on the Deloitte Technology Fast 500™ , a ranking of th...
Aytu Biopharma, Inc. (AYTU) Q1 2022 Earnings Conference Call November 16, 2021, 4:30 PM ET Company Participants Josh Disbrow – Chairman and Chief Executive Officer Richard Eisenstadt – Chief Financial Officer Conference Call Participants Jennifer Kim – Cantor Fitzgerald P...
Aytu BioScience (NASDAQ:AYTU): Q1 GAAP EPS of -$1.09 misses by $0.60. Revenue of $22M (+62.7% Y/Y) misses by $0.1M. Press Release Ended quarter with approximately $40.6 million in cash, cash equivalents and restricted cash For further details see: Aytu BioScience EPS misses by $0.60, mi...
Quarterly net revenue increased 62% to $21.9 million Ended quarter with approximately $40.6 million in cash, cash equivalents and restricted cash Fully integrated and expanding RxConnect patient support program and salesforce drove growth across prescription portfolio Planned ...
Aytu BioScience (NASDAQ:AYTU) is scheduled to announce Q1 earnings results on Monday, November 15th, after market close. The consensus EPS Estimate is -$0.08 and the consensus Revenue Estimate is $22.1M. Over the last 3 months, EPS estimates have seen 0 upward revision and 1 downward. Revenue...
ENGLEWOOD, CO / ACCESSWIRE / November 8, 2021 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company focused on commercializing novel therapeutics and consumer healthcare products, announced today that it will host a conference call and live webcast on November 15, 2021, at...
(This release corrects the previous one that was issued on September 7, 2021 to reflect the time of the Cantor Presentation being changed to 2:40 pm EST) ENGLEWOOD, CO / ACCESSWIRE / September 30, 2021 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company focused on c...
Aytu Biopharma, Inc. (AYTU) Q4 2021 Earnings Conference Call September 27, 2021, 04:30 PM ET Company Participants Josh Disbrow - Chairman and CEO Richard Eisenstadt - CFO Conference Call Participants Jennifer Kim - Cantor Fitzgerald Vernon Bernardino - H.C. Wainwright Presentation Operator Go...
Quarterly net revenue increased 74% sequentially to $23.5M; 138% year-over-year to $65.6M Ended quarter with approximately $50M in cash, cash equivalents and restricted cash Planned pivotal study for AR101 in Vascular Ehlers-Danlos Syndrome (VEDS) to begin in 1H22; scientific advis...
News, Short Squeeze, Breakout and More Instantly...
Company receives proceeds of $3.5 million through exercise of warrants, a portion of which was used to pay down debt Interest rate on new $13.0 million term loan reduced by approximately 350 basis points today, potentially saving the Company $1.3 million over the life of the term loan T...
Phoenix, Arizona and New York, New York--(Newsfile Corp. - May 29, 2024) - Lytham Partners, a leading investor relations and corporate access firm, today announced the schedule for its Spring 2024 Investor Conference taking place virtually on May 30, 2024. More than 40 companies will be available...
DENVER, CO / ACCESSWIRE / May 23, 2024 / Aytu BioPharma, Inc. (the Company or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, today announced that Josh Disbrow, CEO, will participate in a webcasted fireside chat and host one-on-one meetings with inv...